Helicobacter DNA in bile: correlation with hepato-biliary diseases.

Abstract:

BACKGROUND:Helicobacter has been identified in isolated cases of hepato-biliary diseases, but its role in the pathogenesis of these conditions remains unclear. AIM:To determine whether Helicobacter could be detected in bile obtained at endoscopic retrograde cholangiopancreatography, and to evaluate the prevalence of this infection in patients with hepato-biliary diseases. METHODS:Bile was collected from 125 patients with various hepato-biliary diseases undergoing endoscopic retrograde cholangiopancreatography. Among them, 75 were diagnosed with biliary stones, 15 with pancreatico-biliary malignancies and four with primary sclerosing cholangitis. The detection of Helicobacter in DNA extracted from these bile samples was performed using Helicobacter genus-specific primers (capable of detecting 100-1000 organisms/mL). RESULTS:Helicobacter was detected in all positive controls. Only three samples had polymerase chain reaction inhibitors. All remaining bile samples (122 patients with hepato-biliary diseases) were negative for Helicobacter DNA. CONCLUSIONS:Helicobacter can be detected in bile samples using polymerase chain reaction. This infection, however, was not present in any of our patients diagnosed with gallstones or hepato-biliary malignancies, raising doubt as to the possible association between Helicobacter and these entities. Given the low sample size of patients with primary sclerosing cholangitis, more studies are required to determine whether an association exists with this condition.

journal_name

Aliment Pharmacol Ther

authors

Fallone CA,Tran S,Semret M,Discepola F,Behr M,Barkun AN

doi

10.1046/j.1365-2036.2003.01424.x

subject

Has Abstract

pub_date

2003-02-01 00:00:00

pages

453-8

issue

3

eissn

0269-2813

issn

1365-2036

pii

1424

journal_volume

17

pub_type

杂志文章
  • A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.

    abstract:BACKGROUND:Conventional interferon monotherapy fails to achieve virological clearance in most hepatitis C-infected patients. The use of high-dose induction regimens may improve the initial clearance of virus, while the addition of ribavirin appears to improve the rates of sustained response once clearance is achieved. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01201.x

    authors: Malik AH,Kumar KS,Malet PF,Ostapowicz G,Adams G,Wood M,Yarbrough K,Jones A,Lee WM

    更新日期:2002-03-01 00:00:00

  • The sequential organ failure assessment (SOFA) score is an effective triage marker following staggered paracetamol (acetaminophen) overdose.

    abstract:BACKGROUND:The sequential organ failure assessment (SOFA) score is an effective triage marker following single time point paracetamol (acetaminophen) overdose, but has not been evaluated following staggered (multiple supratherapeutic doses over >8 h, resulting in cumulative dose of >4 g/day) overdoses. AIM:To evaluate...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05102.x

    authors: Craig DG,Zafar S,Reid TW,Martin KG,Davidson JS,Hayes PC,Simpson KJ

    更新日期:2012-06-01 00:00:00

  • Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study.

    abstract:BACKGROUND:Gastroprotective strategies are recommended for nonsteroidal anti-inflammatory drug (NSAID) users at risk of upper gastrointestinal (UGI) complications. AIM:To compare the use of gastroprotective strategies in NSAID users in three countries, and the subsequent impact of rofecoxib withdrawal. METHODS:We con...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12028

    authors: Valkhoff VE,van Soest EM,Masclee GM,de Bie S,Mazzaglia G,Molokhia M,Kuipers EJ,Sturkenboom MC

    更新日期:2012-10-01 00:00:00

  • The effects of low doses of ranitidine on intragastric acidity in healthy men.

    abstract:BACKGROUND:H2-receptor antagonists are becoming widely available as over-the-counter medications for the treatment of heartburn and excess gastric acidity. AIM:To determine the effects of single low doses of ranitidine on intragastric acidity. METHODS:Intragastric pH was measured for 9 h after lunch in five studies i...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1998.00307.x

    authors: Wyeth JW,Pounder RE,Sercombe JC,Snell CC

    更新日期:1998-03-01 00:00:00

  • Short report: long-term management of peptic ulcer disease with ranitidine in Germany.

    abstract::One hundred and twenty-five patients with duodenal ulcer disease were given continuous ranitidine therapy after initial acute healing. Cumulative remission rates indicated that 95% of patients were ulcer-free after 1 year, 89% at 2 years, 81% at 3 years, 70% at 4 years and 60% at 5 and 6 years. Nine patients had a sec...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2036.1994.tb00171.x

    authors: Simon B,Schütz E,Müller P,Dixon JS

    更新日期:1994-02-01 00:00:00

  • Twenty-four-hour intragastric acidity and nocturnal gastric secretion in gastric ulcer patients--the effects of cimetidine.

    abstract::In a double-blind randomized study, the profile of 24-h intragastric acidity and nocturnal gastric secretion was measured in a group of patients with healed gastric ulcer on placebo and 400 mg cimetidine b.d. and 800 mg nocte. Neither cimetidine regimen significantly decreased daytime intragastric acidity, but the 800...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1990.tb00472.x

    authors: Derodra JK,Howden CW,Burget DW,Hunt RH

    更新日期:1990-06-01 00:00:00

  • Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids.

    abstract:BACKGROUND:We have observed an increase in hepatotoxicity (DILI) reporting related to the use of anabolic androgenic steroids (AAS) for bodybuilding. AIM:To characterise phenotype presentation, outcome and severity of AAS DILI. METHODS:Data on 25 cases of AAS DILI reported to the Spanish (20) and Latin-American (5) D...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13023

    authors: Robles-Diaz M,Gonzalez-Jimenez A,Medina-Caliz I,Stephens C,García-Cortes M,García-Muñoz B,Ortega-Alonso A,Blanco-Reina E,Gonzalez-Grande R,Jimenez-Perez M,Rendón P,Navarro JM,Gines P,Prieto M,Garcia-Eliz M,Bessone F,Brahm

    更新日期:2015-01-01 00:00:00

  • Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation.

    abstract:BACKGROUND:Symptoms of irritable bowel syndrome are often cyclical and thus may require repeated rather than continuous therapy. Tegaserod is effective and well-tolerated for irritable bowel syndrome with constipation but data on retreatment are lacking. AIM:To assess whether tegaserod retreatment is as efficacious an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.2004.02294.x

    authors: Müller-Lissner S,Holtmann G,Rueegg P,Weidinger G,Löffler H

    更新日期:2005-01-01 00:00:00

  • Mycophenolate mofetil in refractory inflammatory bowel disease.

    abstract:BACKGROUND:Mycophenolate mofetil has been claimed to be effective and well tolerated in refractory inflammatory bowel disease although there is little information regarding its use in clinical practice. AIM:To review our experience in achieving and maintaining remission in refractory inflammatory bowel disease and to ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01581.x

    authors: Ford AC,Towler RJ,Moayyedi P,Chalmers DM,Axon AT

    更新日期:2003-06-01 00:00:00

  • High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection.

    abstract:BACKGROUND:Helicobacter pylori infection may persist after both first- and second-line current treatments. AIM:To assess the efficacy of a third-line, culture-guided treatment approach for the eradication of H. pylori. METHODS:Patterns of resistance were analysed in H. pylori isolates from 94 consecutive patients in ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.01910.x

    authors: Cammarota G,Martino A,Pirozzi G,Cianci R,Branca G,Nista EC,Cazzato A,Cannizzaro O,Miele L,Grieco A,Gasbarrini A,Gasbarrini G

    更新日期:2004-04-01 00:00:00

  • The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment - Prompt Endoscopy (CADET-PE) study.

    abstract:BACKGROUND:Uninvestigated dyspepsia is common in family practice. The prevalence of clinically significant upper gastrointestinal findings (CSFs) in adult uninvestigated dyspepsia patients, and their predictability based on history, is unknown. METHODS:Prompt endoscopy was performed within 10 days of referral, in 1040...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01646.x

    authors: Thomson AB,Barkun AN,Armstrong D,Chiba N,White RJ,Daniels S,Escobedo S,Chakraborty B,Sinclair P,Van Zanten SJ

    更新日期:2003-06-15 00:00:00

  • Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.

    abstract:BACKGROUND:Gastro-oesophageal reflux disease (GERD) is an important problem in systemic sclerosis due to impaired salivation and oesophageal function. AIM:To determine the efficacy of adding ranitidine at bedtime to control nocturnal acid breakthrough (NAB) and GERD in patients with systemic sclerosis already prescrib...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2007.03469.x

    authors: Janiak P,Thumshirn M,Menne D,Fox M,Halim S,Fried M,Brühlmann P,Distler O,Schwizer W

    更新日期:2007-11-01 00:00:00

  • End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome.

    abstract:BACKGROUND:Methotrexate (MTX) is one of the most frequently prescribed drugs in contemporary medicine with a well-recognised hepatotoxic potential, for which stringent laboratory and histological surveillance has long been advocated. AIM:To estimate the population burden of end-stage methotrexate-related liver disease...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12912

    authors: Dawwas MF,Aithal GP

    更新日期:2014-10-01 00:00:00

  • Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms.

    abstract:BACKGROUND:Little is known about the distinctive characteristics of subjects with frequent (at least weekly) and occasional gastro-oesophageal reflux symptoms. AIM:To compare the characteristics and disease management of subjects complaining of at least weekly and less frequent gastro-oesophageal reflux symptoms. MET...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02811.x

    authors: Bretagne JF,Honnorat C,Richard-Molard B,Caekaert A,Barthélemy P

    更新日期:2006-03-01 00:00:00

  • NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum?

    abstract::Eighteen healthy volunteers were included in a cross-over, double-blind study where 500 mg naproxen b.d. was given for 1 week with 20 mg famotidine b.d., 40 mg nocte or placebo. Endoscopic evaluation of the gastroduodenal mucosa was performed before and after each treatment period, with separate evaluation of the mid-...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1990.tb00474.x

    authors: Aabakken L,Bjørnbeth BA,Weberg R,Viksmoen L,Larsen S,Osnes M

    更新日期:1990-06-01 00:00:00

  • Review article: Strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause.

    abstract:BACKGROUND:As there is considerable overlap between the fasting serum gastrin concentrations found in Zollinger-Ellison syndrome and various common conditions such as Helicobacter pylori infection and acid suppressing medication use, establishing the cause of hypergastrinaemia in individual cases can sometimes be diffi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.03976.x

    authors: Murugesan SV,Varro A,Pritchard DM

    更新日期:2009-05-15 00:00:00

  • Systematic review: worldwide variation in the frequency of coeliac disease and changes over time.

    abstract:BACKGROUND:Coeliac disease (CD), originally thought to be largely confined to Northern Europe and Australasia and uncommon in North America and the Middle East, is now recognised to be equally common in all these countries. It is still thought to be rare in the Orient and Sub-Saharan Africa. AIM:To assess geographical...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12373

    authors: Kang JY,Kang AH,Green A,Gwee KA,Ho KY

    更新日期:2013-08-01 00:00:00

  • Review article: the opportunities and benefits of extended acid suppression.

    abstract::Acid suppression therapy with proton pump inhibitors is associated with well-established benefits in the management of gastro-oesophageal reflux (GERD) and other acid-related disorders. However, a number of issues still remain unsettled. Despite their clinical efficacy, when given once daily, currently available proto...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02945.x

    authors: Scarpignato C,Pelosini I

    更新日期:2006-06-01 00:00:00

  • Review article: irritable bowel syndrome.

    abstract::Irritable bowel syndrome is a disease that can be diagnosed positively on the basis of an established series of criteria and limited exclusion of organic disease. It is the most common disease diagnosed by gastroenterologists and affects about 20% of all people at any one time. Symptoms fluctuate, and the overall prev...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.1997.84256000.x

    authors: Camilleri M,Choi MG

    更新日期:1997-02-01 00:00:00

  • Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration.

    abstract:BACKGROUND:Bismuth compounds prevent gastric injury from the short-term administration of nonsteroidal anti-inflammatory drugs. We studied the mechanisms underlying the gastroprotective actions of bismuth subsalicylate against indomethacin-induced injury in rats. METHODS:An in vivo microscopic technique was used in wh...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1997.00170.x

    authors: Tanaka S,Guth PH,Carryl OR,Kaunitz JD

    更新日期:1997-06-01 00:00:00

  • Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.

    abstract:BACKGROUND:In rheumatoid arthritis and psoriasis female sex has been shown to be associated with discontinuation of anti-tumour necrosis factor-α (TNF-α) therapy. AIM:To retrospectively assess the association between sex and TNF-α drug persistence in patients with inflammatory bowel disease (IBD). METHODS:All IBD pat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15380

    authors: Schultheiss JPD,Brand EC,Lamers E,van den Berg WCM,van Schaik FDM,Oldenburg B,Fidder HH

    更新日期:2019-08-01 00:00:00

  • Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort.

    abstract:BACKGROUND:Surveillance colonoscopy is recommended for inflammatory bowel disease (IBD) patients with longstanding extensive colitis (LEC). AIMS:To assess modalities and results of colonoscopic surveillance in a subset of CESAME cohort patients at high risk of colorectal cancer (CRC) and followed in university French ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04711.x

    authors: Vienne A,Simon T,Cosnes J,Baudry C,Bouhnik Y,Soulé JC,Chaussade S,Marteau P,Jian R,Delchier JC,Coffin B,Admane H,Carrat F,Drouet E,Beaugerie L

    更新日期:2011-07-01 00:00:00

  • Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.

    abstract:BACKGROUND:Historically, the beneficial effects of the nonsystemic oral agent rifaximin on various gastrointestinal (GI) disorders have been attributed to direct antibiotic activity on gut microbiota. However, data are accumulating to suggest that other nonantibacterial effects may be involved in rifaximin efficacy. A...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type:

    doi:10.1111/apt.13406

    authors: DuPont HL

    更新日期:2016-01-01 00:00:00

  • Rifaximin in the treatment of recurrent Clostridium difficile infection.

    abstract:BACKGROUND:Clostridium difficile can cause severe antibiotic-associated colitis. Conventional treatments with metronidazole and vancomycin improve symptoms, but after discontinuation of treatment, C. difficile infection (CDI) recurs in a number of patients. Rifaximin is a rifamycin-based non-systemic antibiotic that ha...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12111

    authors: Mattila E,Arkkila P,Mattila PS,Tarkka E,Tissari P,Anttila VJ

    更新日期:2013-01-01 00:00:00

  • Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study.

    abstract:BACKGROUND:Delta virus (HDV)-related chronic hepatitis is difficult to treat. AIMS:To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen seroconversion. METHODS:Thirty-one hepatitis B ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2005.02542.x

    authors: Niro GA,Ciancio A,Tillman HL,Lagget M,Olivero A,Perri F,Fontana R,Little N,Campbell F,Smedile A,Manns MP,Andriulli A,Rizzetto M

    更新日期:2005-08-01 00:00:00

  • Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation.

    abstract:BACKGROUND:Although lactulose and polyethylene glycol are osmotic laxatives widely used in the treatment of chronic constipation, no study has been conducted to compare their actions on the colonic bacterial ecosystem, which has an important influence on host health. AIM:To assess the effects of lactulose and polyethy...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2004.01918.x

    authors: Bouhnik Y,Neut C,Raskine L,Michel C,Riottot M,Andrieux C,Guillemot F,Dyard F,Flourié B

    更新日期:2004-04-15 00:00:00

  • 13C-Methacetin metabolism in patients with cirrhosis: relation to disease severity, haemoglobin content and oxygen supply.

    abstract:BACKGROUND:Hypoxia may contribute to impairment of liver function and thus interfere with results of liver tests. In patients with cirrhosis, cytochrome P-450 mediated metabolism of substrates is facilitated in the presence of supplemental oxygen. It has not been studied how this relates to liver function and haemoglob...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01604.x

    authors: Zipprich A,Meiss F,Steudel N,Sziegoleit U,Fleig WE,Kleber G

    更新日期:2003-06-15 00:00:00

  • Mucosal penetration and clearance of gluten and milk antigens in eosinophilic oesophagitis.

    abstract:BACKGROUND:The Th2 allergic pathway in eosinophilic oesophagitis (EoE) responds to food antigen exposure. AIM:To compare the presence and temporal pattern of food antigen penetration in oesophageal mucosa in active and inactive EoE and controls METHODS: Thirty-two patients with EoE (20 active) and 10 controls were ask...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16180

    authors: Ravi A,Marietta EV,Alexander JA,Peterson K,Lavey C,Geno DM,Murray JA,Katzka DA

    更新日期:2021-02-01 00:00:00

  • Review article: COX-2, prostanoids and colon cancer.

    abstract::Epidemiological, experimental, and clinical studies have demonstrated that colon carcinogenesis may be prevented by nonsteroidal anti-inflammatory drugs (NSAIDs). Although controversy remains, recent studies, including ours, have revealed that NSAIDs suppress colon carcinogenesis at the adenoma stage where cyclooxygen...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.16.s2.8.x

    authors: Ota S,Bamba H,Kato A,Kawamoto C,Yoshida Y,Fujiwara K

    更新日期:2002-04-01 00:00:00

  • The organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients.

    abstract:BACKGROUND:Intravenous octreotide is an established treatment of oesophageal variceal haemorrhage in the cirrhotic patient. AIM:To examine the organ extraction and splanchnic haemodynamic effects of octreotide in cirrhotic patients with portal hypertension. METHODS:Thirteen patients with cirrhosis had hepatic venous ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.1998.00353.x

    authors: Ottesen LH,Flyvbjerg A,Møller S,Bendtsen F

    更新日期:1998-07-01 00:00:00